Drugs / Vi Polysaccharide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00326443 | Feb 2006 → Sep 2007 | typhoid fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01437267 Comparator | Oct 2011 → Aug 2012 | typhoid fever | Novartis | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vi Polysaccharide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01437267 ↗ |
| Modality | Vaccine | “licensed purified Vi polysaccharide vaccine” NCT00326443 ↗ |
| Route | Intramuscular | “Three weeks later, all volunteers will receive 25 micrograms (0.5 ml) of licensed purified Vi polysaccharide vaccine by the intramuscular route.” NCT00326443 ↗ |